Tim F. Greten

Thoracic and Gastrointestinal Oncology Branch
The Center for Cancer Research
United States of America

Professor Immunology
Biography

Tim F. Greten, M.D., received his medical training at Christian Albrechts University in Kiel, Germany in 1993. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), in the laboratory of Drew Pardoll and Liz Jaffee, where he initiated his work in the field of tumor immunology. In 1999 Dr. Greten returned to Hannover Medical School, where he finished his training in internal medicine (2003), medical oncology (2004) and gastroenterology (2007). He held an associate professor position in the Department of Gastroenterology, Hepatology and Endocrinology. In February 2010 Dr. Greten joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015. Dr. Greten has published more than 150 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC. Currently, Dr. Greten serves on the Center of Excellence in Immunology Steering Committee and Center for Advanced Preclinical Research oversight committee. He is a Chairperson of the CCR Scientific Protocol Review.  

Research Intrest

Cancer Biology, Clinical Research, Immunology 

List of Publications
Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, et al. (2013) Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol 59: 1007-1013.
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. (2016) Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatology.
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, et al. (2016) Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell 30: 533-547.
Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, et al. (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531: 253-257.